



WIR MACHEN

KLINIKUM

MU

CLINICAL CASE PRESENTATION

Martin Dreyling

Medizinische Klinik III

LMU München




Munich, Germany



Multicenter Evaluation of MCL

Annency Criteria fulfilled

event free interval after chemotherapy in stages III + IV




anthra, anthracycline; MCL, mantle cell lymphoma

MUNICH 2018

Dreyling, ASCO 1999

MCL: a spectrum of disease



MCL, mantle cell lymphoma

CASE 1

.

•


•

•

- Female, born 1932
- Retired textile designer, from Denmark
- Previously healthy
- 2016 lymphocytosis detected (10 x $10^{9}/L$), normal haemoglobin and platelet count
- CT scan shows abdominal lymphadenopathy, up to 2 cm in size, spleen slightly enlarged
 - Bone marrow biopsy shows 25% CD20+/CD5+/CyclinD1+ cells mantle cell lymphoma
 - No symptoms



MCL: two kind of diseases





BM, bone marrow; IG, immunoglobulin; MC, mantle cell; MCL, mantle cell lymphoma; neg, negative; PB, peripheral blood. MCL, mantle cell lymphoma Drey



Annals of Oncology 28 (Supplement 4): iv62-iv71, 2017 doi:10.1093/annonc/mdx223

CLINICAL PRACTICE GUIDELINES

Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up[†]

M. Dreyling¹, E. Campo², O. Hermine³, M. Jerkeman⁴, S. Le Gouill⁵, S. Rule⁶, O. Shpilberg⁷, J. Walewski⁸ & M. Ladetto⁹, on behalf of the ESMO Guidelines Committee^{*}

¹Department of Medicine III, University Hospital – LMU Munich, Munich, Germany; ²Hematopathology Section, Hospital Clinic of Barcelona, University of Barcelona, Barcelona, Spain; ³Department of Hematology, Imagine Institute and Descartes University, INSERM U1163 and CNRS ERL 8564, Necker Hospital, Paris, France; ⁴Department of Hematology, University Lund, Lund, Sweden; ⁵CHU de Nantes, Service d'Hématologie Clinique, Université de Nantes, Nantes, France; ⁶Peninsula School of Medicine and Dentistry, University of Plymouth, Plymouth, UK; ⁷Institute of Hematology, Assuta Medical Center, Tel-Aviv, Israel; ⁸Department of Lymphoid Malignancy, Maria Sklodowska-Curie Institute and Oncology Centre, Warsaw, Poland; ⁹Divisione di Ematologia, Azienda Ospedaliera Santi Antonio e Biagio e Cesare Arrigo, Alessandria, Italy



MCL: ESMO Clinical Practice Guidelines


Leukaemic non-nodal subtype of MCL

However, a subset of patients may exhibit a more indolent evolution. Most of these cases are commonly characterised by a leukaemic non-nodal presentation with BM involvement only and splenomegaly [1, 8]. SOX11 negativity may help to identify these cases. In addition, conventional MCL (SOX11-positive) with low Ki-67 ($\leq 10\%$) tend to have a more indolent course.

Unfortunately, there are no markers that definitely predict indolent behaviour, but a short course of 'watch and wait' period under close observation seems to be appropriate in suspected indolent cases with low tumour burden [III, B] [10].



MCL: ESMO Clinical Practice Guidelines




ongress

MUNICH 2018 ASCT, autologous stem cell transplantation; BAC, bendamustine and cytarabine; BR, bendamustine and rituximab; Ara-C, cytarabine; CHOP, cyclophosphamide, doxorubicin, vincristine and prednisone; CVP, cyclophosphamide, vincristine and prednisone; R, rituximab; VR-CAP, rituximab, cyclophosphamide, doxorubicin and prednisone with bortezomib.



- In February 2018, she is started on R-bendamustine. Bendamustine dose reduced to 50% (1 day only). 6 cycles are planned
- After 2 cycles, she is hospitalised due to dyspnoea and fever, and diagnosed with a pneumocystis pneumonia. Treated with cotrimoxazole, and discharged after 10 days
- After 4 cycles, she asked to stop due to worsening fatigue. By then, lymphocytosis is normalised, no remaining lymphadenopathy or splenomegaly
- No maintenance rituximab is planned
- In August 2018, two months after stopping treatment, the patient feels well





Rummel, ASH 2017: #483

CASE 2


- Man born 1953
- Social worker
- Previously diagnosed with mitral insufficiency and impaired hearing
- November 2016 admitted at local hospital with suspected acute lymphocytic leukemia (ALL)

WBC 320 x 10⁹/L, hepatosplenomegaly, general lymphadenopathy Immunophenotyping peripheral blood: MCL, t(11;14)+

- Initally treated as ALL with corticosteroids, vincristine, cyclophosphamide, but WBC -> 450
- Blood sample analysed for TP53 mutation positive



Risk factor proliferation: MCL 35



С

1.0

0.8

0.4

0.2

0.0

0 1 2

Log-rank for trend P < .001

3

OS (proportion) 0.6 **Risk Group**

Standard risk

Low risk

5 6

Time (years)

High risk

HR

1

(95% CI)

Reference


P = .03

P = .03

8 9 10

0.43 (0.13 to 0.99)


2.47 (1.01 to 8.69)






Scott, JCO 2017

MCL: ESMO Clinical Practice Guidelines



ASCT, autologous stem cell transplantation; BAC, bendamustine and cytarabine; BR, bendamustine and rituximab; Ara-C, cytarabine; CHOP, cyclophosphamide, doxorubicin, vincristine and prednisone; CVP, cyclophosphamide, vincristine and prednisone; R, rituximab; VR-CAP, rituximab, cyclophosphamide, doxorubicin and prednisone with bortezomib.








Hermine, Lancet 2016


LyMa trial





Le Gouill, NEJM 2017

Survival rates from randomisation





Le Gouill, NEJM 2017


CASE 2

- Man born 1953
- Received high dose cytarabine as in Nordic MCL2 only transient response
- Started on rituximab + ibrutinib 560 mg/day
- March 2017 CR. Unrelated donor identified. Allo-SCT planned ASAP.
 Patient hesitant prefers to wait until after summer
- August 2017 minimal bone marrow involvement
- September 2017 bulky abdominal mass
- Ibrutinib resistance stopped, started on R-bendamustine
- After 2 weeks rapid progression bilateral hydronephrosis dies Oct 2017 due to progressive MCL




Allo-SCT, allogeneic hematopoietic stem cell transplantation; MCL, mantle cell lymphoma

MCL: ESMO Clinical Practice Guidelines






MCL3001 (RAY): Phase 3 Study





MCL, mantle cell lymphoma; PD, progressive disease; WBC, white blood cell Drey

Progression-free survival (PFS)




At a 2-year landmark, the PFS rate was 41% for ibrutinib versus 7% for temsirolimus Investigator-assessed HR for ibrutinib versus temsirolimus was 0.43 (95% CI, 0.32-0.58)

MUNICH 2018

Dreyling, Lancet 2015


Independent predictors of PFS and OS with Ibrutinib: Multivariate Analysis



Clinical risk factors and number of prior lines predict outcome in R/R MCL

MCL, mantle cell lymphoma; OS, overall survival; PFS, progression-free survival

Relapsed mantle cell lymphoma Failure under ibrutinib





Martin, Blood 2016

European MCL Network Study generation 2018

< 65 years	> 60 years	> 65 years
MCL younger:	MCL elderly R2:	MCL elderly I:
R-CHOP/DHAP =>ASCT	R-CHOP vs R-CHOP/Ara-C	BR +/- Ibrutinib
R-CHOP/DHAP+I =>ASCT => I	=> Rituximab M	=> Rituximab M
R-CHOP/DHAP + I => I	+/- Lenalidomide	+/- Ibrutinib

Relapse

Ibrutinib/Bortezomib	R-HAD +/- Bortezomib	lbrutinib +/- ABT-199
----------------------	----------------------	--------------------------



Acknowledgements



